Kristina G. Maxwell

Kristina G. Maxwell

Auto-generated profile, based on publicly available information

Kristina G. Maxwell

Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Stem Cell Reports
Verified
Journal Article
Open access
LVLeonardo Velazco-Cruz
Leonardo Velazco-Cruz
JSJiwon Song
Jiwon Song
KMKristina G. Maxwell
Kristina G. Maxwell
MGMadeleine M. Goedegebuure
Madeleine M. Goedegebuure
PAPunn Augsornworawat
Punn Augsornworawat
JMJeffrey R. Millman
Jeffrey R. Millman
Recent advances in human pluripotent stem cell (hPSC) differentiation protocols have generated insulin-producing cells resembling pancreatic β cells. While these stem cell-derived β (SC-β) cells are capable of undergoing glucose-stimulated insulin secretion (GSIS), insulin secretion per cell remains low compared with islets and cells lack dynamic insulin release. Herein, we report a differentiation strategy focused on modulating transforming growth factor β (TGF-β) signaling, controlling cellular cluster size, and using an enriched serum-free media to generate SC-β cells that express β cell markers and undergo GSIS with first- and second-phase dynamic insulin secretion. Transplantation of these cells into mice greatly improves glucose tolerance. These results reveal that specific time frames for inhibiting and permitting TGF-β signaling are required during SC-β cell differentiation to achieve dynamic function. The capacity of these cells to undergo GSIS with dynamic insulin release makes them a promising cell source for diabetes cellular therapy.

24 February 2020 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
NHNathaniel J. Hogrebe
Nathaniel J. Hogrebe
PAPunn Augsornworawat
Punn Augsornworawat
KMKristina G. Maxwell
Kristina G. Maxwell
LVLeonardo Velazco-Cruz
Leonardo Velazco-Cruz
JMJeffrey R. Millman
Jeffrey R. Millman
Generation of pancreatic β cells from human pluripotent stem cells (hPSCs) holds promise as a cell replacement therapy for diabetes. In this study, we establish a link between the state of the actin cytoskeleton and the expression of pancreatic transcription factors that drive pancreatic lineage specification. Bulk and single-cell RNA sequencing demonstrated that different degrees of actin polymerization biased cells toward various endodermal lineages and that conditions favoring a polymerized cytoskeleton strongly inhibited neurogenin 3-induced endocrine differentiation. Using latrunculin A to depolymerize the cytoskeleton during endocrine induction, we developed a two-dimensional differentiation protocol for generating human pluripotent stem-cell-derived β (SC-β) cells with improved in vitro and in vivo function. SC-β cells differentiated from four hPSC lines exhibited first- and second-phase dynamic glucose-stimulated insulin secretion. Transplantation of islet-sized aggregates of these cells rapidly reversed severe preexisting diabetes in mice at a rate close to that of human islets and maintained normoglycemia for at least 9 months.

22 April 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KMKristina G. Maxwell
Kristina G. Maxwell
PAPunn Augsornworawat
Punn Augsornworawat
LVLeonardo Velazco-Cruz
Leonardo Velazco-Cruz
MKMichelle H. Kim
Michelle H. Kim
RARie Asada
Rie Asada
JMJeffrey R. Millman
Jeffrey R. Millman
Patient stem cell–derived β cells corrected for a diabetes-causing variant in WFS1 restore glucose homeostasis when transplanted into diabetic mice.

2 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
XWXi Wang
Xi Wang
KMKristina G. Maxwell
Kristina G. Maxwell
KWKai Wang
Kai Wang
DBDaniel T. Bowers
Daniel T. Bowers
JFJames A. Flanders
James A. Flanders
MMMinglin Ma
Minglin Ma
A nanofibrous cell encapsulation device containing rodent/human islets or human stem cell–derived β cells treats diabetes in rodents.

2 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMarlie M. Maestas
Marlie M. Maestas
MIMatthew Ishahak
Matthew Ishahak
PAPunn Augsornworawat
Punn Augsornworawat
DVDaniel A. Veronese-Paniagua
Daniel A. Veronese-Paniagua
KMKristina G. Maxwell
Kristina G. Maxwell
JMJeffrey R. Millman
Jeffrey R. Millman
Diabetes involves the death or dysfunction of pancreatic β-cells. Analysis of bulk sequencing from human samples and studies using in vitro and in vivo models suggest that endoplasmic reticulum and inflammatory signaling play an important role in diabetes progression. To better characterize cell type-specific stress response, we perform multiplexed single-cell RNA sequencing to define the transcriptional signature of primary human islet cells exposed to endoplasmic reticulum and inflammatory stress. Through comprehensive pair-wise analysis of stress responses across pancreatic endocrine and exocrine cell types, we define changes in gene expression for each cell type under different diabetes-associated stressors. We find that β-, α-, and ductal cells have the greatest transcriptional response. We utilize stem cell-derived islets to study islet health through the candidate gene CIB1, which was upregulated under stress in primary human islets. Our findings provide insights into cell type-specific responses to diabetes-associated stress and establish a resource to identify targets for diabetes therapeutics.

22 September 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
RKRie Asada Kitamura
Rie Asada Kitamura
KMKristina G. Maxwell
Kristina G. Maxwell
WYWenjuan Ye
Wenjuan Ye
KKKelly Kries
Kelly Kries
CBCris M. Brown
Cris M. Brown
FUFumihiko Urano
Fumihiko Urano
Wolfram syndrome is a rare genetic disorder largely caused by pathogenic variants in the WFS1 gene and manifested by diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration. Recent genetic and clinical findings have revealed Wolfram syndrome as a spectrum disorder. Therefore, a genotype-phenotype correlation analysis is needed for diagnosis and therapeutic development. Here, we focus on the WFS1 c.1672C>T, p.R558C variant, which is highly prevalent in the Ashkenazi Jewish population. Clinical investigation indicated that patients carrying the homozygous WFS1 c.1672C>T, p.R558C variant showed mild forms of Wolfram syndrome phenotypes. Expression of WFS1 p.R558C was more stable compared with the other known recessive pathogenic variants associated with Wolfram syndrome. Human induced pluripotent stem cell–derived (iPSC-derived) islets (SC-islets) homozygous for WFS1 c.1672C>T variant recapitulated genotype-related Wolfram syndrome phenotypes. Enhancing residual WFS1 function through a combination treatment of chemical chaperones mitigated detrimental effects caused by the WFS1 c.1672C>T, p.R558C variant and increased insulin secretion in SC-islets. Thus, the WFS1 c.1672C>T, p.R558C variant causes a mild form of Wolfram syndrome phenotypes, which can be remitted with a combination treatment of chemical chaperones. We demonstrate that our patient iPSC–derived disease model provides a valuable platform for further genotype-phenotype analysis and therapeutic development for Wolfram syndrome.